Plain-English translation of NCT07125729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two blood-based tests—called Haystack and Signatera—that look for tiny traces of cancer in your bloodstream after colorectal cancer surgery. These tests are designed to catch cancer recurrence much earlier than traditional imaging scans, potentially when the cancer is easier to treat. The study will compare how well these two tests perform in detecting cancer that may return.
Current methods for detecting colorectal cancer recurrence often rely on imaging scans that can miss very early signs of returning cancer. These new blood tests may be able to detect cancer cells circulating in your blood months before a scan would show a recurrence, giving doctors a chance to intervene sooner.
You likely qualify if…
You likely don't qualify if…
You will have blood samples collected before your surgery, then again 3–10 weeks after surgery. After that, you'll return for blood draws every 3 months for the first 2 years, then every 6 months for years 3 through 5. The study will last up to 5 years total, and your samples will be tested with both blood tests to see which one is better at catching early signs of cancer return. You'll also need to allow the research team to use your archived tumor tissue to personalize the tests to your specific cancer.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States